Sygnature Discovery

SEPTEMBER 11, 2024

Compound Screening Fragment Based Drug Discovery supported by Crystallography or SPR & MST. Covalent compound binding by mass spectrometry. Protein Characterisation & Quality Control Mass spectrometry – intact protein, peptide mapping and native. NMR, FIDA, ITC, SEC-MALS and FSEC. SPR, DLS, MST, FTSA and CETSA.

Science 52

Science Compound Screening RNA Protein Expression 52

Sygnature Discovery

SEPTEMBER 5, 2024

Tecan is housed in a controlled humidity and temperature-controlled room to reduce moisture absorption during any compound handling operation. Compound Screening: Our HTS and ASMS are housed within our Compound Management Facility allowing them to seamlessly utilise the same sample management software, ensuring a rapid turnaround time.

Compound Screening 52

Compound Screening Production Drugs 52

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. SB is based in Glasgow and employs 55 people.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

The Pharma Data

JANUARY 6, 2021

The pharma industry is witnessing a steep rise in the use of AI-driven solutions in early-stage drug discovery, deep-learning technologies for compound screening, and lead identification and automation enhancements in the lab. Next-generation digital technologies are having an immense impact on the drug discovery process.

Cell Based Assays 52

Cell Based Assays Compound Screening Organic Chemistry DNA 52

The ChEMBL-og

APRIL 16, 2024

New Deposited Datasets CHEMBL5291702 - European Medicines Agency CHEMBL5303304 - EUbOPEN Chemogenomics Library - IncuCyte (assays link to document CHEMBL4689842) CHEMBL5303761 - Data for DCP probe BI-3231 CHEMBL5303762 - Data for DCP probe BI-8668 CHEMBL5303763 - Data for DCP probe BI-3802 CHEMBL5303764 - Data for DCP probe BI-3812 CHEMBL5303765 - (..)

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108

KIF1A

AUGUST 28, 2024

” While the primary focus of CIRM grants has been cell therapy, it has also promoted the use of cell-based disease modeling and compound screening, as well as the development of gene-based therapies.

Therapies 52

Therapies Compound Screening Research Treatment 52

Drug Target Review

NOVEMBER 1, 2023

We need to build the assays that we need for compound screening. Can you elaborate on how these techniques are integrated into your research process and how they contribute to advancing cancer drug discovery? We are involved from a very early stage once a target is validated.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96